A success case of reformulating a protein with therapeutic skin regeneration activity, to enhance its stability, delivery, and efficacy.
An article titled "Recombinant Human Epidermal Growth Factor/Quatsome Nanoconjugates: A Robust Topical Delivery System for Complex Wound Healing" has been recently published in March 2021 in Advanced Therapeutics Journal (Wiley Online Library). In this paper the development and deep characterization of new DELOS Nanovesicles are described as a potential nanomedicine for the topical treatment of complex wounds, particularly diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
In the publication a soft, reliable, and scalable method based on our proprietary DELOS platform is reported for obtaining these nanoconjugates of recombinant human epidermal growth factor and DELOS nanovesicles. These nanoconjugates exhibit appropriate values of the major critical quality attributes of colloidal nanomedicines, such as controlled and narrow nanoscopic particle size distribution (which play important roles in determining their stability), drug loading, drug release, drug protection, targeting ability, and bioactivity. Also, they exhibit a dual action by 1) inbuilt antimicrobial activity preventing infections and 2) promoting regeneration of granulation tissue and re-epithelialization with complete closure of complex wounds.